HomeAI · summaries
Storia in 7 fonti
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks
By acquiring Crinetics Pharmaceuticals, Vertex is staking its place alongside other big biotechs such as Gilead, Regeneron and Biogen.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
markets.businessinsider.com
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceut...
- ·
endpoints.news
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.
